177 related articles for article (PubMed ID: 11463551)
21. Differentiating benign and malignant pulmonary lesions with FDG-PET.
Yang SN; Liang JA; Lin FJ; Kwan AS; Kao CH; Shen YY
Anticancer Res; 2001; 21(6A):4153-7. PubMed ID: 11911310
[TBL] [Abstract][Full Text] [Related]
22. Detection of unknown primary tumours and distant metastases in patients with cervical metastases: value of FDG-PET versus conventional modalities.
Regelink G; Brouwer J; de Bree R; Pruim J; van der Laan BF; Vaalburg W; Hoekstra OS; Comans EF; Vissink A; Leemans CR; Roodenburg JL
Eur J Nucl Med Mol Imaging; 2002 Aug; 29(8):1024-30. PubMed ID: 12173016
[TBL] [Abstract][Full Text] [Related]
23. PET imaging of musculoskeletal tumours with fluorine-18 alpha-methyltyrosine: comparison with fluorine-18 fluorodeoxyglucose PET.
Watanabe H; Inoue T; Shinozaki T; Yanagawa T; Ahmed AR; Tomiyoshi K; Oriuchi N; Tokunaga M; Aoki J; Endo K; Takagishi K
Eur J Nucl Med; 2000 Oct; 27(10):1509-17. PubMed ID: 11083540
[TBL] [Abstract][Full Text] [Related]
24. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of pulmonary lesions with FDG-PET. Comparison of findings in patients with and without a history of prior malignancy.
Knight SB; Delbeke D; Stewart JR; Sandler MP
Chest; 1996 Apr; 109(4):982-8. PubMed ID: 8635381
[TBL] [Abstract][Full Text] [Related]
26. First clinical results of (D)-18F-Fluoromethyltyrosine (BAY 86-9596) PET/CT in patients with non-small cell lung cancer and head and neck squamous cell carcinoma.
Burger IA; Zitzmann-Kolbe S; Pruim J; Friebe M; Graham K; Stephens A; Dinkelborg L; Kowal K; Schibli R; Luurtsema G; Maas B; Horn-Tutic M; Haerle SK; Wiegers J; Schaefer NG; Hany TF; von Schulthess GK
J Nucl Med; 2014 Nov; 55(11):1778-85. PubMed ID: 25256060
[TBL] [Abstract][Full Text] [Related]
27. PET-FDG scan enhances but does not replace preoperative surgical staging in non-small cell lung carcinoma.
Poncelet AJ; Lonneux M; Coche E; Weynand B; Noirhomme P;
Eur J Cardiothorac Surg; 2001 Sep; 20(3):468-74; discussion 474-5. PubMed ID: 11509265
[TBL] [Abstract][Full Text] [Related]
28. Clinical relevance of imaging proliferative activity in lung nodules.
Buck AK; Hetzel M; Schirrmeister H; Halter G; Möller P; Kratochwil C; Wahl A; Glatting G; Mottaghy FM; Mattfeldt T; Neumaier B; Reske SN
Eur J Nucl Med Mol Imaging; 2005 May; 32(5):525-33. PubMed ID: 15599526
[TBL] [Abstract][Full Text] [Related]
29. Value of positron emission tomography for lung cancer staging.
Albes JM; Dohmen BM; Schott U; Schülen E; Wehrmann M; Ziemer G
Eur J Surg Oncol; 2002 Feb; 28(1):55-62. PubMed ID: 11869015
[TBL] [Abstract][Full Text] [Related]
30. 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax.
Demura Y; Tsuchida T; Ishizaki T; Mizuno S; Totani Y; Ameshima S; Miyamori I; Sasaki M; Yonekura Y
J Nucl Med; 2003 Apr; 44(4):540-8. PubMed ID: 12679397
[TBL] [Abstract][Full Text] [Related]
31. [18F]FDG imaging of head and neck tumours: comparison of hybrid PET and morphological methods.
Dresel S; Grammerstorff J; Schwenzer K; Brinkbäumer K; Schmid R; Pfluger T; Hahn K
Eur J Nucl Med Mol Imaging; 2003 Jul; 30(7):995-1003. PubMed ID: 12739070
[TBL] [Abstract][Full Text] [Related]
32. Efficiency of 18F-FDG and 99mTc-depreotide SPECT in the diagnosis of malignancy of solitary pulmonary nodules.
Halley A; Hugentobler A; Icard P; Porret E; Sobrio F; Lerochais JP; Bouvard G; Zalcman G; Agostini D
Eur J Nucl Med Mol Imaging; 2005 Sep; 32(9):1026-32. PubMed ID: 15877227
[TBL] [Abstract][Full Text] [Related]
33. 18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT).
Lassen U; Daugaard G; Eigtved A; Damgaard K; Friberg L
Eur J Cancer; 1999 Jul; 35(7):1076-82. PubMed ID: 10533451
[TBL] [Abstract][Full Text] [Related]
34. Positron emission tomographic imaging with fluorodeoxyglucose isefficacious in evaluating malignant pulmonary disease.
Graeber GM; Gupta NC; Murray GF
J Thorac Cardiovasc Surg; 1999 Apr; 117(4):719-27. PubMed ID: 10096967
[TBL] [Abstract][Full Text] [Related]
35. Clinical role of (18)F-FDG PET for initial staging of patients with extrahepatic bile duct cancer.
Kato T; Tsukamoto E; Kuge Y; Katoh C; Nambu T; Nobuta A; Kondo S; Asaka M; Tamaki N
Eur J Nucl Med Mol Imaging; 2002 Aug; 29(8):1047-54. PubMed ID: 12173019
[TBL] [Abstract][Full Text] [Related]
36. Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: correlation with histopathology.
Jensen TK; Holt P; Gerke O; Riehmann M; Svolgaard B; Marcussen N; Bouchelouche K
Scand J Urol Nephrol; 2011 Mar; 45(2):122-8. PubMed ID: 21231796
[TBL] [Abstract][Full Text] [Related]
37. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
Schaefferkoetter JD; Carlson ER; Heidel RE
J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
[TBL] [Abstract][Full Text] [Related]
38. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses.
Ozülker T; Ozülker F; Ozbek E; Ozpaçaci T
Nucl Med Commun; 2011 Apr; 32(4):265-72. PubMed ID: 21301376
[TBL] [Abstract][Full Text] [Related]
39. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma.
Kollmannsberger C; Oechsle K; Dohmen BM; Pfannenberg A; Bares R; Claussen CD; Kanz L; Bokemeyer C
Cancer; 2002 May; 94(9):2353-62. PubMed ID: 12015760
[TBL] [Abstract][Full Text] [Related]
40. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
